EGFR and neoplasm: The principal drug targets for existing drugs include insulin‐like growth factor (IGF)‐R, EGFR, PDGF/PDGFR, mTOR, VEGFR, and Aurora kinase pathways linked to cellular growth, immune checkpoint pathways linked to immunity, relay immune cell therapy, and tumor vaccines (Figure 5).